The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Welcome back, Mike33. Once again we have your propaganda on behalf of Kromek. My final thoughts on the Article in the Times: It is people like Basu and companies like Kromek who give the Aim market a dodgy reputation. There are many good companies in the Aim market.. Kromek is probably the worst.
Doing a quick check where the 4 tier one medical imaging OEMs are with thier CZT based Photon counting CT development programs its apparent GE, Siemens and Canon are all steaming ahead and have Prototype scanners in testing at university hospitals and are making very positive claims of their benefits and beliefs that CZT photo counting Scanners married with deep learning AI software will bring and be the new gold standard of CT medical diagnostic imagining.
Canon has units back in Japan now (Redlen CZT) and will be undergoing full testing from Jan 24.
Link below -
https://global.medical.canon/News/PressRelease/Detail/142192-834
Siemens has updated it's web site -
and is presently building a new purpose built CZT manufacturing
Plant in Germany after initially acquiring a Japanese CZT company.
"Quantum Technology® is transforming CT by introducing photon-counting technology into clinical routine. At its core is the QuantaMax® detector, which is equipped with a crystal semiconductor that is substantially different from a standard scintillation detector."
GE is only just slightly ahead of Canon it seems-
"A new prototype GE HealthCare photon counting CT (PCCT) scanner has been installed at 3155 Porter Drive, only the second such scanner in the United States." (California)
So Kromek's new multi year
Development/Supply contact with Philips the 4th listed global tier one OEM will surely advance at pace, they won't and can't afford to lose thier hard fought market share to the competition.
And to deny this revenue steam will have any material impact on Kromek's fortunes seem somewhat absurd to me.
If the article results in a 10% plus rise in the share price, he can give as many interviews as he likes.
Nd
Good point skid. Indeed actually picking what is probably the worst Aim share takes some doing. Basu has been making promises since 2017 on a regular basis. only a fool will believe that one day his promise will come true. Well it is the pantomime season !!!!!!
Iron.
The standard of business and personal finance ‘journalism’ in the times is kindergarten level. Just seems like summer interns.
There is a real story here on how the London market values companies, choosing kmk and basu as poster boys so far off the mark.
I've just read the Times reader's comments and concluded that this must be one of the most loathed stocks in the FTSE Aim All Share. If I were Basu, I think I'd keep a low profile having lost so many investors so much money over the years. I definitely wouldn't crow about turning EBITDA positive. We're not that stupid!
I stopped reading the Times several years ago. No disrespect, but surely readers of that paper are not so dumb as to buy into this snake oil salesmans pitch. Basu and his chums on the BoD do not invest in "their" wonderful company despite the fat salaries they pay themselves. That tells you ALL you need to know.
Anyone got link or text for Times article ?
Revenue and improved margins might be fact. Unfortunately the losses widened to £7.5 million in July . Guess we will see in the interims if this fact has been changed. Would be a first for the company
Timing is important.....The company has turned profitable....and is increasing revenue....2 facts that should see this multibag....The right time to invest is now.....before the crowds arrive....
600 million shares for a company with a market cap of 27 million pounds tells the story of a company with annual dilution for its entire existence. Never having made a profit they coul apply for charitable status, or non profit making organisation. 2 raises and a loan note with the undoubted issuance of more shares to add to the ever frying number of shares. Yet it’s up 10% this morning on no news. The market knows alright. It’s the ordinary shareholder who is left in the dark and penniless.
Funny that at these super bargain levels basu isn't diverting at least half of his very far salary into buying shares on the open market.
I can't believe, after that write up, some buffoons are buying this morning thinking Basu is some sort of tech AIM messiah.
the below is from terminator101 over on advfn.
i see that basu is complaining in the times that the “market dosen’t understand the strategic value of kromek”. when useless directors take to the press to complain about the market it’s worth examining in detail if they have grounds for that complaint. let’s see:
*their last financing “deal” put millions of death spiral finance in place at a high interest rate.
*they have never made a single penny of profit in over a decade.
*directors have barely any skin in the game, the most being 0.7%. hardly backing themselves.
*promise for next year is to be ebitda positive, which means they will make yet another whopping loss.
*two of the directors are creaming more than a quarter of a million in salary every year. that means they have extracted more in salary in a decade than the entire mcap of the company.
strategic value my ****. it’s a crappy aim company run by a bunch of greedy pedestrian scientists, and at £24 million mcap for an enterprise that lost £7 million last year, is massively overvalued. worth at best circa £5 million or less than 1p. it’s a slam dunk short.
Just read this and the attempt at PR knocked by all the comments on his perforrmance.
Basu seems to have been schooled by Bozos Johnson in delusion, self pity and complete lack of self awareness.
Has he been taking lessons from p###o price Andrew or mone?
DYOR and only personal opinion - but suspect many PI's also regret the decision about listing the company!
Article today about Mr Basu's regrets about listing the company.
Had a better relationship with private investors - "very challenging for retail investors to really understand a small, complex business ".
Might encourage more interest in the business?
Nd
Ironknut. I concur.
Billy i think he sold out at 5p when he was coming out with all that big talk. At any event i think he like the BoD will have nothing to say.
Only mick33 can answer that. Wonder what he’s thinking next now. Having said that, I wonder whether he’s even invested.
Come on mick33. Reveal!
Down into the threes.
The problem with having a CEO and senior team who have failed to execute for such an extended period without a break, no news is taken as a bad sign.
Perhaps the overpaid CEO and board would show the way by digging out their piggy banks and buying.
Come on, mick33. Investors are waiting desperately for your advice.
Everyone off loading again.
Can u explain mick33
Yawn indeed Same message as 2018 2019 2020 2021 2022 now 2023. No doubt coming soon in 2024. Only mugs are listening now. Is this person trying to convince himself . Say it often enough and it will come true.
YAWN. @mike33